ADMA ADMA Biologics Inc
Company Analysis
Latest News
🟢 ADMA Biologics is trading 5.3% up in pre-market with catalyst unconfirmed
ADMA Biologics is trading at $11.30 (+5.31%) in pre-market; the cause of the move remains unconfirmed. - On October 15, the company announced peer-reviewed...
🟢 ADMA Biologics is trading 4.1% up today amid study reporting IVIG impurity removal
ADMA Biologics is trading 4.11% higher at $10.77 alongside study news; the release did not explicitly link it to the share-price move. - On October 15, 2026, a...
🟢 ADMA Biologics is trading 4.22% up
ADMA Biologics is trading at $10.13, up 4.22%, with the specific driver of the gain unclear. - No clear company-specific catalyst was found for October 5,...
🟢 ADMA Biologics is trading 4.1% up
ADMA Biologics is trading at $9.77, up 4.10%; the reason for the September 28 gain remains unclear. - The company’s investor-relations releases list no...
🟢 ADMA Biologics is trading 54% up in after-hours trading; catalyst remains unclear
ADMA Biologics is trading 54% higher at $15.15 after-hours on September 22, 2026; no company-specific catalyst has been identified. - The move follows a...
🟢 ADMA Biologics is trading 4.23% up today as major indexes rise
ADMA Biologics is trading +4.23% at $9.49 amid a broad September 21, 2026 risk-on rally. • The S&P 500, Nasdaq, and Dow Jones are all higher, supporting...
🔴 ADMA Biologics is trading 5% down today after board-breach investigation announcement
ADMA Biologics is trading 5.25% down now at $8.66 after Berger Montague announced a September 14, 2026 investigation into potential board breaches tied to...
ADMA Biologics Faces Investor Investigation Over Allegations of Misleading Statements and Breaches of Fiduciary Duties
ADMA Biologics is the subject of an investigation announced by the Shareholders Foundation, Inc. on behalf of long-term investors. The probe centers on...
ADMA Biologics Downgraded, Facing BIVIGAM Slump and Lowered 2026 Guidance
Analysts downgraded ADMA Biologics to a Hold rating on September 2, 2026. The move follows a deceleration in growth and a reduction in revenue guidance for...
BlackRock's 16.5% Stake in ADMA Biologics Signals Big-Money Confidence, but Can a Plasma Drug Company Justify the Hype?
Shares of ADMA Biologics surged 9.2% to $10.20 on August 31, bucking a softer broader market, after BlackRock disclosed ownership of roughly 38.4 million...
🟢 ADMA Biologics is trading 9.21% up in pre-market after BlackRock disclosed a 16.5% stake
ADMA Biologics is trading 9.21% up in pre-market at $10.20 after BlackRock disclosed ownership of 38,355,684 shares, representing about 16.5% of the...
BlackRock acquires 16.5% stake in ADMA Biologics for $321 million
BlackRock Inc. disclosed a new investment in ADMA Biologics on August 27, 2026. The asset manager acquired 38,355,684 shares of the biotechnology firm during...
🟢 ADMA Biologics is trading 4.7% up in pre-market amid broader risk-on sentiment
ADMA Biologics is trading 4.7% up at $10.00, most likely reflecting broader risk-on sentiment after no new company-specific announcement was identified for...
🟢 ADMA Biologics is trading 7.5% up in pre-market on positive Moderna and Merck Phase 3 results
ADMA Biologics is trading 7.5% up at $10.80, primarily on biotech-sector strength following positive Phase 3 personalized cancer-vaccine results from Moderna...
🟢 ADMA Biologics rises 4.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Bank of America doubles ADMA Biologics stake, joining major institutional investors
Bank of America Corp DE increased its ADMA Biologics Inc. holdings by 107.5% during the first quarter. An August 15, 2026, SEC filing confirms the bank...
🔴 ADMA Biologics is trading 4.55% down today after Berger Montague announces fiduciary-duty probe
ADMA Biologics is trading 4.55% down at $9.34 after Berger Montague announced an investigation into potential fiduciary-duty breaches by the board, including...
ADMA Biologics Board Investigated, Citing Potential Fiduciary Duty Breaches
Berger Montague PC is investigating the Board of Directors of ADMA Biologics, Inc. for potential breaches of fiduciary duty. This probe follows a series of...
ADMA Biologics Surges 10% on a Profit Beat, but Can One Star Product Carry a Company With a Shrinking Second Act?
Shares shifted sharply higher as ADMA Biologics jumped 10% to $10.19 on August 7, two days after its second-quarter earnings revealed a company being remade by...
ADMA Biologics Surges 10% on a Profit Beat, but Can One Star Product Carry a Company With a Shrinking Second Act?
Shares shifted sharply higher as ADMA Biologics jumped 10% to $10.19 on August 7, two days after its second-quarter earnings revealed a company being remade by...